The Oxford Parkinson's Disease Centre (OPDC) is a unique multidisciplinary research program at the University of Oxford supported by Parkinson’s UK with funds from The Monument Trust, one of the Sainsbury Family Charitable Trusts.
Established in February 2010, the OPDC brings together internationally-renowned scientists who work on the genetics of Parkinson’s, the generation of cell and animal models, and the wiring of brain circuits which control movement, with clinical experts in the diagnosis and treatment of Parkinson’s.
Our world-class research centre works to understand the earliest events in the development of Parkinson’s with an ultimate view to target the molecular mechanisms of disease with neuroprotective therapies to prevent disease onset or delay progression.
Our program is focused on the molecular pathways to Parkinson’s in order to:
- Understand the progression of Parkinson’s
- Predict the onset of Parkinson’s
- Identify potential drug targets for Parkinson’s
- Develop new treatments that will prevent the development of Parkinson’s in at-risk individuals.
Watch the video below to learn more about OPDC's research:
Monday, 19 April 2021, 1pm to 2pm
Monday, 17 May 2021, 1pm to 2pm
Revisiting dopamine-acetylcholine imbalance in Parkinson’s disease: glutamate co-transmission as an exciting partner in crime
CRAGG S. and Zhang Y-F., (2021), Neuron
Axonal Modulation of Striatal Dopamine Release by Local γ-Aminobutyric Acid (GABA) Signalling.
Roberts BM. et al, (2021), Cells, 10
Validation of α-synuclein in L1CAM-immunocaptured exosomes as a biomarker for the stratification of Parkinsonian syndromes
TOFARIS G., (2021), Movement Disorders
Olfactory Testing in Parkinson's Disease & REM Behavior Disorder: A Machine Learning Approach.
Lo C. et al, (2021), Neurology
Dopaminergic imaging and clinical predictors for phenoconversion of REM sleep behaviour disorder.
Arnaldi D. et al, (2021), Brain, 144, 278 - 287
REST protects dopaminergic neurons from mitochondrial and α-synuclein oligomer pathology in an alpha synuclein overexpressing BAC-transgenic mouse model.
Ryan BJ. et al, (2021), J Neurosci